Clinical Trial

Detection of Minimal Residual Disease Using Exosomal miRNA Distant Metastasis Markers

Study acronym: DESTINEX-REM
Recruiting
View on ClinicalTrials.gov →
Summary
Gastric cancer (GC) is a leading cause of cancer-related death worldwide. Even in patients undergoing curative surgery for non-metastatic disease, postoperative recurrence frequently occurs due to undetected minimal residual disease (MRD). This study aims to establish a highly sensitive and specific liquid biopsy assay using exosomal microRNAs (exo-miRNAs) to detect MRD and predict distant metastasis before clinical recurrence.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-11-17.
Trial Details
NCT Number NCT07243015
Lead Sponsor City of Hope Medical Center
Conditions Gastric Cancer
Enrollment 500 participants
Start Date 2025-01-15
Primary Completion 2028-06-18 (estimated)
Study Completion 2028-06-18 (estimated)
Updated on ClinicalTrials.gov 2026-07-06